Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin

G. R. Corazza, M. Ventrucci, A. Strocchi, M. Sorge, L. Pranzo, R. Pezzilli, G. Gasbarrini

Research output: Contribution to journalArticlepeer-review

Abstract

In twelve patients affected by small bowel bacterial overgrowth, diagnosed by means of the lactulose hydrogen breath test, the therapeutic efficacy of a non-absorbable derivative of rifamycin, rifaximin, was evaluated. This study showed that this drug has a satisfactory therapeutic efficacy in contaminated small bowel syndrome and, at the doses tested, is free of side-effects.

Original languageEnglish
Pages (from-to)312-316
Number of pages5
JournalJournal of International Medical Research
Volume16
Issue number4
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin'. Together they form a unique fingerprint.

Cite this